MSN Labs launches generic Favipiravir tablets for COVID-19 treatment
The Hindu
MSN Laboratories on Wednesday said it has launched the generic version of antiviral drug Favipiravir in 800 mg strength for treating mild and moderate COVID-19 patients.The company's drug to be so
MSN Laboratories on Wednesday said it has launched the generic version of antiviral drug Favipiravir in 800 mg strength for treating mild and moderate COVID-19 patients. The company's drug to be sold under the brand name 'Favilow 800 mg' is priced at ₹ 144 per tablet and will be available across pharmacies, MSN Laboratories said in a statement. "In the light of increasing COVID-19 cases in India, affordable treatment options are the need of the hour to flatten the curve. We are sure that our product Favilow 800 would help support the nation's efforts in overcoming the COVID crisis," MSN Group Chairman and Managing Director MSN Reddy said.More Related News
Air India has signed an agreement with Bengaluru Airport City Limited (BACL), a subsidiary of Bangalore International Airport Limited (BIAL), to develop a built-to-suit facility for the AME program that will feature modern classrooms, well-equipped laboratories for practical training and a team of qualified trainers.